CHOLESTYRAMINE Drug Patent Profile
✉ Email this page to a colleague
When do Cholestyramine patents expire, and what generic alternatives are available?
Cholestyramine is a drug marketed by Ajanta Pharma Ltd, Alkem Labs Ltd, Ani Pharms, Epic Pharma Llc, Ivax Sub Teva Pharms, Par Pharm, Tagi, Teva, Upsher Smith Labs, Zydus Pharms, and Teva Pharms. and is included in seventeen NDAs.
The generic ingredient in CHOLESTYRAMINE is cholestyramine. There are eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cholestyramine
A generic version of CHOLESTYRAMINE was approved as cholestyramine by EPIC PHARMA LLC on August 15th, 1996.
Summary for CHOLESTYRAMINE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 17 |
Finished Product Suppliers / Packagers: | 12 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 37 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CHOLESTYRAMINE |
DailyMed Link: | CHOLESTYRAMINE at DailyMed |
Recent Clinical Trials for CHOLESTYRAMINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Loxo Oncology, Inc. | Phase 1 |
Eli Lilly and Company | Phase 1 |
Ain Shams University | Phase 4 |
Pharmacology for CHOLESTYRAMINE
Drug Class | Bile Acid Sequestrant |
Mechanism of Action | Bile-acid Binding Activity |